Paul B. Manning, Director at Candel Therapeutics, Inc. (CADL), bought 550,458 shares at $5.45 ($3.0M) on 2026-02-23, disclosed to the SEC on 2026-02-26.
Open-market purchase of $3.0M CADL by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Nothing distinguishes this filing.
| Filing → |
| LQDA | SELL | 2025-09-02 | $37.9M | — | Filing → |
| TSHA | BUY | 2025-06-03 | $2.1M | — | Filing → |
| CADL | BUY | 2024-12-18 | $7.5M | — | Filing → |